
|Videos|July 24, 2014
Early Treatment With Docetaxel for Metastatic Prostate Cancer
Author(s)Jyoti D. Patel, MD
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
Advertisement
Clinical Pearls
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
- Treatment with docetaxel early on improves survival for men who have early evidence of metastatic prostate cancer.
- Some patients have performance status that precludes treatment. As a result, they are never treated with the most active agents.
- This analysis will change practice: It will change who cares for patients early on and how they are treated.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































